Threshold Pharmaceuticals Coverage Initiated by Analysts at Brean Capital (THLD)
Equities researchers at Brean Capital assumed coverage on shares of Threshold Pharmaceuticals (NASDAQ:THLD) in a research report issued on Tuesday. The firm set a “buy” rating and a $15.00 price target on the stock. Brean Capital’s price target would indicate a potential upside of 265.85% from the stock’s previous close.
Separately, analysts at Zacks upgraded shares of Threshold Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, April 29th.
Shares of Threshold Pharmaceuticals (NASDAQ:THLD) traded down 0.49% on Tuesday, hitting $4.08. The stock had a trading volume of 346,672 shares. Threshold Pharmaceuticals has a one year low of $3.51 and a one year high of $6.05. The stock’s 50-day moving average is $3.97 and its 200-day moving average is $4.46. The company’s market cap is $242.1 million.
Threshold Pharmaceuticals (NASDAQ:THLD) last announced its earnings results on Thursday, May 1st. The company reported ($0.12) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.10) by $0.02. Analysts expect that Threshold Pharmaceuticals will post $-0.51 EPS for the current fiscal year.
Threshold Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of drugs targeting the microenvironment of solid tumors and the bone marrows of some hematologic malignancies (NASDAQ:THLD) as treatments for patients living with cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.